Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling
Abstract The phenomenon of mixed/heterogenous treatment responses to cancer therapies within an individual patient presents a challenging clinical scenario. Furthermore, the molecular basis of mixed intra-patient tumor responses